Daniel Sturm, PharmD

Scientific Director, US Medical Affairs
Incyte Corporation

Poster(s):

• (107) Real-world effect of ruxolitinib cream: decreased use of additional topical therapies and limited escalation to systemic treatments
  Wednesday, October 29, 2025